Allosteric Inhibition of P-Glycoprotein-Mediated Efflux by DMH1

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• P-glycoprotein (P-gp) actively exports drugs, causing multidrug resistance and reducing chemotherapy effectiveness.
• Existing P-gp inhibitors lack clinical approval due to toxicity, poor specificity, and limited efficacy.
• This study explores DMH1, a type I BMP receptor inhibitor, as a potential P-gp inhibitor.

Purpose of the Study:

• To investigate DMH1's potential as a novel P-glycoprotein (P-gp) inhibitor.
• To evaluate DMH1's efficacy in overcoming P-gp-mediated multidrug resistance.
• To elucidate the mechanism of DMH1's P-gp inhibition.

Main Methods:

• Cytotoxicity assays (MTT) in P-gp-overexpressing and deficient cell lines.
• Calcein AM retention and daunorubicin accumulation assays to assess P-gp inhibition.
• Kinetic analysis, ATPase activity assays, and molecular docking to determine inhibition mechanism.

Main Results:

• DMH1 exhibited no cytotoxicity across tested cell lines.
• DMH1 significantly increased intracellular accumulation of Calcein AM and daunorubicin.
• Kinetic analysis indicated noncompetitive, allosteric inhibition by DMH1, with reduced Vmax and unchanged Km.
• DMH1 dose-dependently inhibited P-gp ATPase activity, and docking suggested allosteric binding.

Conclusions:

• DMH1 acts as a noncompetitive, allosteric P-gp inhibitor.
• DMH1 enhances intracellular drug retention without associated cytotoxicity.
• DMH1 represents a promising lead compound for developing new strategies to overcome multidrug resistance and improve chemotherapy outcomes.